UBS upgraded Alkermes (NASDAQ:ALKS) to Buy from Neutral on Tuesday, citing prospects for Irish biotech’s orexin 2 receptor ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy volunteers. ORX142 is the second drug candidate ...